PF Prism CV

JUN 30, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Xeljanz (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling change to tofacitinib (Xeljanz); regulatory action only, no clinical trial data reported.